Literature DB >> 33146896

Incorporating patient generated health data into pharmacoepidemiological research.

Alison Bourke1, William G Dixon2, Andrew Roddam3, Kueiyu Joshua Lin4, Gillian C Hall5, Jeffrey R Curtis6, Sabine N van der Veer7, Montse Soriano-Gabarró8, Juliane K Mills9, Jacqueline M Major10, Thomas Verstraeten11, Matthew J Francis12, Dorothee B Bartels13.   

Abstract

Epidemiology and pharmacoepidemiology frequently employ Real-World Data (RWD) from healthcare teams to inform research. These data sources usually include signs, symptoms, tests, and treatments, but may lack important information such as the patient's diet or adherence or quality of life. By harnessing digital tools a new fount of evidence, Patient (or Citizen/Person) Generated Health Data (PGHD), is becoming more readily available. This review focusses on the advantages and considerations in using PGHD for pharmacoepidemiological research. New and corroborative types of data can be collected directly from patients using digital devices, both passively and actively. Practical issues such as patient engagement, data linking, validation, and analysis are among important considerations in the use of PGHD. In our ever increasingly patient-centric world, PGHD incorporated into more traditional Real-Word data sources offers innovative opportunities to expand our understanding of the complex factors involved in health and the safety and effectiveness of disease treatments. Pharmacoepidemiologists have a unique role in realizing the potential of PGHD by ensuring that robust methodology, governance, and analytical techniques underpin its use to generate meaningful research results.
© 2020 John Wiley & Sons Ltd.

Entities:  

Keywords:  big data; data privacy; digital epidemiology; mobile apps; mobile health; patient generated health data; patient reported outcomes; pharmacoepidemiology; real world data; real world evidence; social media

Year:  2020        PMID: 33146896     DOI: 10.1002/pds.5169

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  2 in total

Review 1.  Factors Contributing to Best Practices for Patient Involvement in Pharmacovigilance in Europe: A Stakeholder Analysis.

Authors:  Monica van Hoof; Katherine Chinchilla; Linda Härmark; Cristiano Matos; Pedro Inácio; Florence van Hunsel
Journal:  Drug Saf       Date:  2022-08-25       Impact factor: 5.228

2.  Post-COVID-19 Syndrome: Leveraging the Patient Perspective and Technological Innovations to Enable the Delineation of Effective Treatments.

Authors:  Matthew T Roe; Bray Patrick-Lake; Andrew C von Eschenbach
Journal:  Drugs       Date:  2021-06-16       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.